latest update:
[TrialBase DB]

trial summary · NCT07802821

A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Small Cell Lung Cancer

A Phase III, Randomized, Controlled, Open-label Clinical Study to Compare the Efficacy and Safety of QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy as First-line Treatment in Participants With Extensive-stage Small Cell Lung Cancer

Trial record from the TrialBase DB dataset, status RECRUITING, condition Extensive-stage Small Cell Lung Cancer, sponsored by Qilu Pharmaceutical Co., Ltd.. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07802821phase PHASE3enrollment 556start 2026-10-27

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

This trial is a Phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of QLC5508 in combination with QL2107 versus Tislelizumab plus platinum and etoposide as first-line treatment in participants with extensive-stage small cell lung cancer.

Source record: https://clinicaltrials.gov/study/NCT07802821

Facts

registry idNCT07802821
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE3
study typeINTERVENTIONAL
lead conditionExtensive-stage Small Cell Lung Cancer
sponsorQilu Pharmaceutical Co., Ltd.
sponsor classINDUSTRY
enrollment556
start date2026-10-27
primary completion2029-03-15
completion2030-06-15
results postednot reported

Conditions

  • Extensive-stage Small Cell Lung Cancer

Interventions

  • QLC5508
  • QL2107
  • Tislelizumab
  • Carboplatin
  • Cisplatin
  • Etoposide

Countries

  • China

Intervention types: DRUG

Work with this record